Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce; R. Gregory Bociek; Ahmed Sawas; Paolo Caimi; Edward Agura; Jeffrey Matous; Stephen M. Ansell; Howland E. Crosswell; Miguel Islas-Ohlmayer; Caroline Behler; Eric Cheung; Andres Forero-Torres; Julie Vose; Owen A. O’Connor; Neil Josephson; Yinghui Wang; Ranjana Advani

doi:10.1111/bjh.16499

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	e86-e90
Journal	British Journal of Haematology
Volume	189
Issue number	3
DOIs	https://doi.org/10.1111/bjh.16499
State	Published - May 1 2020

Keywords

Hodgkin lymphoma
autologous stem cell transplantation
bendamustine
brentuximab vedotin
first salvage therapy

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.16499

Cite this

LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y., & Advani, R. (2020). Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 189(3), e86-e90. https://doi.org/10.1111/bjh.16499

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. / LaCasce, Ann S.; Bociek, R. Gregory; Sawas, Ahmed; Caimi, Paolo; Agura, Edward; Matous, Jeffrey; Ansell, Stephen M.; Crosswell, Howland E.; Islas-Ohlmayer, Miguel; Behler, Caroline; Cheung, Eric; Forero-Torres, Andres; Vose, Julie; O’Connor, Owen A.; Josephson, Neil; Wang, Yinghui; Advani, Ranjana.

In: British Journal of Haematology, Vol. 189, No. 3, 01.05.2020, p. e86-e90.

Research output: Contribution to journal › Letter › peer-review

LaCasce, AS, Bociek, RG, Sawas, A, Caimi, P, Agura, E, Matous, J, Ansell, SM, Crosswell, HE, Islas-Ohlmayer, M, Behler, C, Cheung, E, Forero-Torres, A, Vose, J, O’Connor, OA, Josephson, N, Wang, Y & Advani, R 2020, 'Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma', British Journal of Haematology, vol. 189, no. 3, pp. e86-e90. https://doi.org/10.1111/bjh.16499

LaCasce, Ann S. ; Bociek, R. Gregory ; Sawas, Ahmed ; Caimi, Paolo ; Agura, Edward ; Matous, Jeffrey ; Ansell, Stephen M. ; Crosswell, Howland E. ; Islas-Ohlmayer, Miguel ; Behler, Caroline ; Cheung, Eric ; Forero-Torres, Andres ; Vose, Julie ; O’Connor, Owen A. ; Josephson, Neil ; Wang, Yinghui ; Advani, Ranjana. / Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. In: British Journal of Haematology. 2020 ; Vol. 189, No. 3. pp. e86-e90.

@article{c0a548a32e034b96a5863a0c469f9b1a,

title = "Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma",

keywords = "Hodgkin lymphoma, autologous stem cell transplantation, bendamustine, brentuximab vedotin, first salvage therapy",

author = "LaCasce, {Ann S.} and Bociek, {R. Gregory} and Ahmed Sawas and Paolo Caimi and Edward Agura and Jeffrey Matous and Ansell, {Stephen M.} and Crosswell, {Howland E.} and Miguel Islas-Ohlmayer and Caroline Behler and Eric Cheung and Andres Forero-Torres and Julie Vose and O{\textquoteright}Connor, {Owen A.} and Neil Josephson and Yinghui Wang and Ranjana Advani",

note = "Funding Information: The institutions of Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero‐Torres, Julie Vose, Owen A. O{\textquoteright}Connor, and Ranjana Advani received funding from Seattle Genetics, Inc. to conduct the trial. Howland E. Crosswell, Neil Josephson, and Yinghui Wang, have equity ownership in Seattle Genetics, Inc. Julie Vose and Ahmed Sawas have received honoraria from Seattle Genetics, Inc. Jeffrey Matous and Caroline Behler have participated in a speakers{\textquoteright} bureau for Seattle Genetics, Inc and Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceuticals Limited. Owen A. O{\textquoteright}Connor has received research funding from Seattle Genetics, Inc. Howland E. Crosswell has acted as a consultant for and has received travel expenses from Seattle Genetics, Inc. Neil Josephson was employed by Seattle Genetics, Inc. at the time this research was conducted. Yinghui Wang is employed by Seattle Genetics, Inc. ",

year = "2020",

month = may,

day = "1",

doi = "10.1111/bjh.16499",

language = "English (US)",

volume = "189",

pages = "e86--e90",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

AU - LaCasce, Ann S.

AU - Bociek, R. Gregory

AU - Sawas, Ahmed

AU - Caimi, Paolo

AU - Agura, Edward

AU - Matous, Jeffrey

AU - Ansell, Stephen M.

AU - Crosswell, Howland E.

AU - Islas-Ohlmayer, Miguel

AU - Behler, Caroline

AU - Cheung, Eric

AU - Forero-Torres, Andres

AU - Vose, Julie

AU - O’Connor, Owen A.

AU - Josephson, Neil

AU - Wang, Yinghui

AU - Advani, Ranjana

N1 - Funding Information: The institutions of Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero‐Torres, Julie Vose, Owen A. O’Connor, and Ranjana Advani received funding from Seattle Genetics, Inc. to conduct the trial. Howland E. Crosswell, Neil Josephson, and Yinghui Wang, have equity ownership in Seattle Genetics, Inc. Julie Vose and Ahmed Sawas have received honoraria from Seattle Genetics, Inc. Jeffrey Matous and Caroline Behler have participated in a speakers’ bureau for Seattle Genetics, Inc and Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceuticals Limited. Owen A. O’Connor has received research funding from Seattle Genetics, Inc. Howland E. Crosswell has acted as a consultant for and has received travel expenses from Seattle Genetics, Inc. Neil Josephson was employed by Seattle Genetics, Inc. at the time this research was conducted. Yinghui Wang is employed by Seattle Genetics, Inc.

PY - 2020/5/1

Y1 - 2020/5/1

KW - Hodgkin lymphoma

KW - autologous stem cell transplantation

KW - bendamustine

KW - brentuximab vedotin

KW - first salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85079362224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079362224&partnerID=8YFLogxK

U2 - 10.1111/bjh.16499

DO - 10.1111/bjh.16499

M3 - Letter

C2 - 32048731

AN - SCOPUS:85079362224

VL - 189

SP - e86-e90

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -